Abstract
Diagnosis of latent tuberculosis infection in patients with immune-mediated inflammatory chronic diseases (IMIDs) can be challenged as diagnostic test reliability could be impaired by immunosuppression. We retrospectively analyzed the Quantiferon Gold-Test in-Tube (QFT-G-IT) results of all patients with IMIDs seen at the Department of Internal Medicine of Son Llàtzer Hospital, Palma de Mallorca (Spain), looking for the factors related to QFT-G-IT indeterminate results. During the study period (2008–2015), 520 patients met the inclusion criteria. Factors associated with indeterminate QFT-G-IT results in a univariate analysis were inflammatory bowel disease, disease activity, lymphopenia, and medium-to-high doses of corticosteroids. In a subsequent multivariate analysis, only lymphopenia (defined as < 1500 cells) was associated with indeterminate QFT-G-IT results. Lymphocyte count was the only factor independently associated with an increased number of indeterminate QFT-G-IT results in patients with different autoimmune diseases. Others factors such as the use of medium-to-high doses of corticosteroids should be considered before testing with QFT-G-IT.
Similar content being viewed by others
References
Jick SS, Lieberman ES, Rahman MU et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55:19–26
Carmona L, Hernández-García C, Vadillo C, EMECAR Study Group et al (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436–1439
Iannone F, Cantini F, Lapadula G (2014) Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol 91:41–46
Goletti D, Sanduzzi A, Delogu G (2014) Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol 91:24–31
Maeda T, Banno S, Maeda S et al (2010) Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol 20:18–23
Takeda N, Nojima T, Terao C et al (2011) Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus 20:792–800
González-Martín J, García-García JM, Anibarro L et al (2010) Consensus document on the diagnosis, treatment and prevention of tuberculosis. Enferm Infecc Microbiol Clin 28:297e1–297e120
Bartalesi F, Vicidomini S, Goletti D et al (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33:586–593
Matulis G, Jüni P, Villiger PM et al (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84–90
Bélard E, Semb S, Ruhwald M et al (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17:2340–2349
Cho H, Kim YW, Suh CH et al (2016) Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA. Lupus 25:1341–1348
Shovman O, Anouk M, Vinnitsky N et al (2009) QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 13:1427–1432
Papay P, Eser A, Winkler S et al (2011) Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Investig 41:1071–1076
Jung HJ, Kim TJ, Kim HS et al (2014) Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases. Rheumatol Int 34:1711–1720
Kobashi Y, Sugiu T, Mouri K et al (2009) Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J 33:812–815
Cattamanchi A, Smith R, Steingart KR et al (2011) Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 56:230–238
Aichelburg MC, Tittes J, Breitenecker F et al (2012) Prognostic value of indeterminate IFN-γ release assay results in HIV-1 infection. J Clin Microbiol 50:2767–2769
Oni T, Gideon HP, Bangani N et al (2012) Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment. Clin Vaccine Immunol 19:1243–1247
Karam F, Mbow F, Fletcher H et al (2008) Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS ONE 3:e1441
Sester M, van Leth F, Bruchfeld J, TBNET et al (2014) Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190:1168–1176
Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72
Helwig U, Müller M, Hedderich J et al (2012) Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis 6:419–424
Kleinert S, Kurzai O, Elias J et al (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69:782–784
Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35:776–781
Martin J, Walsh C, Gibbs A et al (2010) Comparison of interferon gamma release assays and conventional screening tests before tumour necrosis factor alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 69:181–185
Hradsky O, Ohem J, Zarubova K et al (2014) Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 58:320–324
Lee H, Park HY, Jeon K et al (2015) QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS ONE 10:e0119260
Mariette X, Baron G, Tubach F et al (2012) Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 71:1783–1790
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest.
Rights and permissions
About this article
Cite this article
González-Moreno, J., García-Gasalla, M., Losada-López, I. et al. IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?. Rheumatol Int 38, 267–273 (2018). https://doi.org/10.1007/s00296-017-3852-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-017-3852-9